key: cord-0807620-vtiwj788
authors: Tripathy, Jaya Prasad
title: Does pandemic justify the use of Hydroxychloroquine for treatment and prevention of COVID‐19 in India?
date: 2020-04-24
journal: J Med Virol
DOI: 10.1002/jmv.25933
sha: 1de74648b7b3c2aa59511488fd894851e7e28c7a
doc_id: 807620
cord_uid: vtiwj788

The Indian Council of Medical Research (ICMR), recommended the use of hydroxychloroquine (HCQ) as a prophylactic against COVID‐19 among health care workers and asymptomatic contacts of laboratory confirmed cases of COVID. This is widely criticised as a hastily taken step with political inclination and minimal evidence backing. In the current scenario, where there is mass fear against COVID‐19, this recommendation has made the people to believe that it will kill the viruses. This has important public health implications which are discussed below. Better communication should have been planned to ensure everyone does not go out and buy it. However, as a nation of 1.3 billion, we need to capitalize on this opportunity to generate data and valuable evidence on the use of HCQ to beat this pandemic. All health care workers taking this drug should volunteer themselves to be part of a trial/observational study and get registered online to generate useful data related to its safety and efficacy and guide future recommendations. The other risk group which includes asymptomatic contacts of laboratory confirmed COVID‐19 patients are under surveillance by the state and local health authorities and could also be roped into this study to generate robust evidence. Of course, pandemic does not just justify the use of HCQ, but pandemic is the time to innovate, think out of box and generate evidence to prove the same so that we can lives. This article is protected by copyright. All rights reserved.

of action of CQ is that it inhibits SARS-CoV replication and spread in cell culture, possibly through reducing glycosylation of the ACE2 receptor which appears to be the primary receptor for entry of SARS-CoV-2 into various epithelial tissues. 11, 12 The action of CQ in reduction of hyperglycemia, which is a significant risk factor for disease severity also needs to explored further. 11 Human trials of HCQ against COVID-19 have so far yielded mixed results. A study among hospitalized patients with confirmed COVID-19 in Marseille, France showed significant reduction/disappearance in viral load with HCQ and azithromycin treatment. 13 However, these results are widely debated due to some methodological issues primarily related to smaller sample size, unmeasured viral load in a majority of the control cohort and non-randomized nature of the trial which might end up cherry picking patients, potentially biasing the results. A randomized trial of HCQ in 30 COVID confirmed patients in China yielded no better clinical benefit compared to the control arm which received standard treatment. 14 Another prospective single-arm study of 11 hospitalized patients in France treated with HCQ and azithromycin (same dosing regimen reported by Gautret et al. 13 ) showed no evidence of viral clearance or clinical benefit with one death and two transferred to the Intensive Care Unit. In another patient, treatment regimen was discontinued after 4 days due to QT prolongation. 15 On the other hand, a preliminary result from a trial from 10 hospitals in China involving 100 patients demonstrated that chloroquine phosphate is superior to the control treatment in preventing the exacerbation of pneumonia, improving lung imaging findings, promoting a virus-negative conversion, and shortening the disease course. 16 Thus, although the intention was to protect the high-risk groups from getting infected, the delivery of the message and implementation could have been better. Rather than discouraging this move by the ICMR, I think all health care workers taking this drug should volunteer themselves to be part of a trial or an observational study to generate evidence related to its safety and efficacy and guide future recommendations. This could have been planned as a multicentric trial or a large observational study with an online recruitment platform where health staff could register and fill their sociodemographic and clinical details, details regarding drug intake and its side effects, COVID exposure and infection. The other risk group which includes asymptomatic contacts of laboratory confirmed COVID-19 patients are under active surveillance by

Effects of chloroquine on viral infections: An old drug against today's diseases?

Chloroquine inhibited ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model

A randomized controlled trial of chloroquine for the treatment of dengue in vietnamese adults

Chloroquine for influenza prevention: A randomised, double-blind, placebo controlled trial

On chikungunya acute infection and chloroquine treatment. Vector-Borne Zoonotic Dis

Hydroxychloroquine, and the COVID-19 Epidemic

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)

No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection. Médecine Mal Infect

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial

Virological and Clinical Cure in Covid-19 Patients Treated with Hydroxychloroquine: A Systematic Review and Meta-Analysis